SNORA35 Interacts with P180 Protein, Potential Drug Target Or Biomarker for Neurodegenerative Disorders

Target Name: SNORA35

NCBI ID: G677816

SNORA35

Other Name(s): HBI-36 | Small nucleolar RNA, H/ACA box 35 | small nucleolar RNA, H/ACA box 35 | SNORA35A

SNORA35 Interacts with P180 Protein, Potential Drug Target Or Biomarker for Neurodegenerative Disorders

SNORA35 (HBI-36) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and kidneys. It is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells. SNORA35 is unique because it is able to interact with several different protein substrates, including the protein known as p180.

The p180 protein is a type of G protein-coupled receptor (GPCR), which is a family of transmembrane proteins that play an important role in cellular signaling. GPCRs are involved in many different processes in the body, including sensory perception, neurotransmitter signaling, and cell survival. The p180 protein is a key regulator of these processes and is involved in the development and maintenance of neural circuits in the brain.

SNORA35 has been shown to interact with the p180 protein in a number of different ways. For example, studies have shown that SNORA35 can bind to the p180 protein with high affinity and that this binding is dose-dependent. This means that as the concentration of SNORA35 increases, the strength of the binding between the two proteins will also increase.

Another way in which SNORA35 has been shown to interact with the p180 protein is through its ability to modulate the activity of the p180 protein. Studies have shown that SNORA35 can inhibit the activation of the p180 protein and that this inhibition is dose-dependent. This means that as the concentration of SNORA35 increases, the p180 protein will not be activated and will not transmit signals to downstream targets.

The potential implications of SNORA35's interaction with the p180 protein are significant. If SNORA35 is a drug target or biomarker for a neurodegenerative disorder, then targeting this protein with drugs that can inhibit its interaction with the p180 protein could be a promising strategy for treating these disorders. Additionally, if SNORA35 is involved in the regulation of neural circuits in the brain, then understanding how it interacts with other proteins in these circuits could provide valuable insights into the underlying mechanisms of neurofunction and neurological disease.

In conclusion, SNORA35 is a protein that has been shown to interact with the p180 protein, a GPCR involved in many different processes in the body. The potential implications of this interaction are significant, andSNORA35 may be a drug target or biomarker for a neurodegenerative disorder. Further research is needed to fully understand how SNORA35 interacts with the p180 protein and to explore its potential as a therapeutic target.

Protein Name: Small Nucleolar RNA, H/ACA Box 35

The "SNORA35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets